Lisanti Capital Growth LLC Buys 185,320 Shares of ARS Pharmaceuticals, Inc. $SPRY

Lisanti Capital Growth LLC lifted its stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 87.8% during the 4th quarter, Holdings Channel reports. The institutional investor owned 396,509 shares of the company’s stock after purchasing an additional 185,320 shares during the quarter. Lisanti Capital Growth LLC’s holdings in ARS Pharmaceuticals were worth $4,619,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Bamco Inc. NY raised its stake in shares of ARS Pharmaceuticals by 3,071.3% in the third quarter. Bamco Inc. NY now owns 1,268,532 shares of the company’s stock worth $12,749,000 after buying an additional 1,228,532 shares during the period. Casdin Capital LLC bought a new position in shares of ARS Pharmaceuticals in the third quarter worth about $16,080,000. American Assets Inc. bought a new position in shares of ARS Pharmaceuticals in the third quarter worth about $553,000. Levin Capital Strategies L.P. raised its stake in shares of ARS Pharmaceuticals by 157.6% in the third quarter. Levin Capital Strategies L.P. now owns 764,294 shares of the company’s stock worth $7,681,000 after buying an additional 467,647 shares during the period. Finally, Aberdeen Group plc raised its stake in shares of ARS Pharmaceuticals by 106.1% in the third quarter. Aberdeen Group plc now owns 3,097,022 shares of the company’s stock worth $31,125,000 after buying an additional 1,594,447 shares during the period. Institutional investors own 68.16% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on SPRY. Wall Street Zen raised ARS Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Zacks Research raised ARS Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 25th. Weiss Ratings downgraded ARS Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 15th. Northland Securities began coverage on ARS Pharmaceuticals in a research note on Thursday, April 9th. They set an “outperform” rating and a $25.00 target price on the stock. Finally, Leerink Partners set a $26.00 target price on ARS Pharmaceuticals and gave the company an “outperform” rating in a research note on Tuesday, March 10th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $28.25.

ARS Pharmaceuticals Stock Down 3.5%

Shares of SPRY opened at $7.94 on Friday. The business’s 50 day moving average is $8.18 and its 200 day moving average is $9.24. The company has a market capitalization of $788.44 million, a PE ratio of -3.95 and a beta of 0.93. ARS Pharmaceuticals, Inc. has a 12-month low of $6.66 and a 12-month high of $18.90. The company has a current ratio of 4.94, a quick ratio of 7.06 and a debt-to-equity ratio of 2.79.

ARS Pharmaceuticals (NASDAQ:SPRY) last issued its earnings results on Friday, May 15th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.08). The business had revenue of $22.68 million for the quarter, compared to the consensus estimate of $22.20 million. ARS Pharmaceuticals had a negative net margin of 200.00% and a negative return on equity of 153.61%. Research analysts expect that ARS Pharmaceuticals, Inc. will post -1.75 earnings per share for the current fiscal year.

ARS Pharmaceuticals Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.